Indications
Ulcerative colitis
Golimumab is a tumor necrosis factor (TNF) blocker indicated for the treatment of adult patients with:
Moderately to severely active rheumatoid arthritis (RA) in combination with methotrexate
Active psoriatic arthritis (PsA) alone, or in combination with methotrexate
Active ankylosing spondylitis (AS)
... Read more
Golimumab is a tumor necrosis factor (TNF) blocker indicated for the treatment of adult patients with:
Moderately to severely active rheumatoid arthritis (RA) in combination with methotrexate
Active psoriatic arthritis (PsA) alone, or in combination with methotrexate
Active ankylosing spondylitis (AS)
Moderate to severe Ulcerative colitis (UC) with an inadequate response or intolerant to prior treatment or requiring continuous steroid therapy inducing and maintaining clinical response, improving endoscopic appearance of the mucosa during induction, inducing clinical remission, achieving and sustaining clinical remission in induction responders
Dosage And Administration
Dosage in Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis: The Golimumab dose regimen is 50 mg administered by subcutaneous injection once a month. For patients with rheumatoid arthritis (RA), Golimumab should be given in combination with methotrexate and for patients with psoriatic arthritis (PsA) or ankylosing spondylitis (AS), Golimumab may be given with or without methotrexate or other nonbiologic Disease Modifying Antirheumatic Drugs (DMARDs). For patients with RA, PsA, or AS, corticosteroids, non-biologic DMARDs, and/or NSAIDs may be continued during treatment with Golimumab.
Dosage in Moderately to Severely Active Ulcerative Colitis: The recommended Golimumab induction dosage regimen is a 200-mg subcutaneous injection at Week 0, followed by 100 mg at Week 2, and then maintenance therapy with 100 mg every 4 weeks.
Side Effects
Most common adverse reactions (incidence > 5%) are upper respiratory tract infection, nasopharyngitis, injection site reactions
Precautions And Warnings
Serious Infections: Do not start Golimumab during an active infection. If an infection develops, monitor carefully, and stop Golimumab if infection becomes serious
Invasive Fungal Infections: For patients who develop a systemic illness on Golimumab, consider empiric antifungal therapy for those who reside in or travel to regions where mycoses are endemic
Hepatitis B Reactivation: Monitor HBV carriers during and several months after therapy. If reactivation occurs, stop Golimumab and begin antiviral therapy
Malignancies: Incidence of lymphoma was greater than in the general U.S. population. Cases of other malignancies have been observed among patients receiving TNF blockers
Congestive Heart Failure: Worsening, or new onset, may occur. Stop Golimumab if new or worsening symptoms occur
Demyelinating Disorders: Exacerbation or new onset may occur
Lupus-like Syndrome: Discontinue Golimumab if symptoms develop
Hypersensitivity Reactions: Serious systemic hypersensitivity reactions including anaphylaxis may occur
Pregnancy And Lactation
There are no adequate and well-controlled trials of Golimumab in pregnant women. There is no information regarding the presence of Golimumab in human milk, the effects on
breastfed infants, or the effects on milk production.